Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Cash from Financing Activities (2016 - 2022)

International Stem Cell (ISCO) has disclosed Cash from Financing Activities for 12 consecutive years, with $250000.0 as the latest value for Q1 2022.

  • On a quarterly basis, Cash from Financing Activities fell 69.66% to $250000.0 in Q1 2022 year-over-year; TTM through Dec 2022 was $250000.0, a 69.66% decrease, with the full-year FY2024 number at -$200000.0, changed N/A from a year prior.
  • Cash from Financing Activities was $250000.0 for Q1 2022 at International Stem Cell, down from $824000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $1.4 million in Q3 2018 to a low of -$53000.0 in Q1 2019.
  • A 4-year average of $543111.1 and a median of $500000.0 in 2019 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 4066.67% in 2019; the steepest drop was 113.52% in 2019.
  • International Stem Cell's Cash from Financing Activities stood at $12000.0 in 2018, then skyrocketed by 4066.67% to $500000.0 in 2019, then skyrocketed by 64.8% to $824000.0 in 2021, then plummeted by 69.66% to $250000.0 in 2022.
  • Per Business Quant, the three most recent readings for ISCO's Cash from Financing Activities are $250000.0 (Q1 2022), $824000.0 (Q1 2021), and $500000.0 (Q4 2019).